Ad is loading...
BPMC
Price
$96.62
Change
+$1.81 (+1.91%)
Updated
Nov 21 closing price
83 days until earnings call
DNLI
Price
$24.22
Change
-$0.20 (-0.82%)
Updated
Nov 21 closing price
101 days until earnings call
Ad is loading...

BPMC vs DNLI

Header iconBPMC vs DNLI Comparison
Open Charts BPMC vs DNLIBanner chart's image
Blueprint Medicines
Price$96.62
Change+$1.81 (+1.91%)
Volume$778.93K
CapitalizationN/A
Denali Therapeutics
Price$24.22
Change-$0.20 (-0.82%)
Volume$1.48M
CapitalizationN/A
BPMC vs DNLI Comparison Chart
Loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
BPMC vs. DNLI commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BPMC is a StrongBuy and DNLI is a StrongSell.

COMPARISON
Comparison
Nov 22, 2024
Stock price -- (BPMC: $96.62 vs. DNLI: $24.22)
Brand notoriety: BPMC and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BPMC: 119% vs. DNLI: 177%
Market capitalization -- BPMC: $6.02B vs. DNLI: $3.51B
BPMC [@Biotechnology] is valued at $6.02B. DNLI’s [@Biotechnology] market capitalization is $3.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $463.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BPMC’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BPMC’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, both BPMC and DNLI are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BPMC’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 3 bullish TA indicator(s).

  • BPMC’s TA Score: 4 bullish, 6 bearish.
  • DNLI’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, BPMC is a better buy in the short-term than DNLI.

Price Growth

BPMC (@Biotechnology) experienced а +1.01% price change this week, while DNLI (@Biotechnology) price change was -14.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was -4.98%, and the average quarterly price growth was +4.01%.

Reported Earning Dates

BPMC is expected to report earnings on Feb 13, 2025.

DNLI is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BPMC($6.02B) has a higher market cap than DNLI($3.52B). DNLI YTD gains are higher at: 12.861 vs. BPMC (4.748). BPMC has higher annual earnings (EBITDA): -75.58M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. BPMC (734M). DNLI has less debt than BPMC: DNLI (52.5M) vs BPMC (471M). BPMC has higher revenues than DNLI: BPMC (434M) vs DNLI (0).
BPMCDNLIBPMC / DNLI
Capitalization6.02B3.52B171%
EBITDA-75.58M-496.05M15%
Gain YTD4.74812.86137%
P/E RatioN/AN/A-
Revenue434M0-
Total Cash734M837M88%
Total Debt471M52.5M897%
FUNDAMENTALS RATINGS
BPMC vs DNLI: Fundamental Ratings
BPMC
DNLI
OUTLOOK RATING
1..100
1963
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
6785
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4648
P/E GROWTH RATING
1..100
7499
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BPMC's Valuation (80) in the Biotechnology industry is in the same range as DNLI (94). This means that BPMC’s stock grew similarly to DNLI’s over the last 12 months.

BPMC's Profit vs Risk Rating (67) in the Biotechnology industry is in the same range as DNLI (85). This means that BPMC’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as BPMC (97). This means that DNLI’s stock grew similarly to BPMC’s over the last 12 months.

BPMC's Price Growth Rating (46) in the Biotechnology industry is in the same range as DNLI (48). This means that BPMC’s stock grew similarly to DNLI’s over the last 12 months.

BPMC's P/E Growth Rating (74) in the Biotechnology industry is in the same range as DNLI (99). This means that BPMC’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BPMCDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
73%
Bearish Trend 5 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
View a ticker or compare two or three
Ad is loading...
BPMC
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLPRX4.880.08
+1.67%
Invesco SteelPath MLP Income C
RREAX29.630.13
+0.44%
Russell Inv Global Real Estate Secs A
AFCGX17.280.07
+0.41%
American Century Focused Intl Gr G
CICAX61.760.17
+0.28%
American Funds Invmt Co of Amer 529A
JCAVX10.39N/A
N/A
JHFunds2 Capital Appreciation Value NAV

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.82%
BEAM - DNLI
63%
Loosely correlated
-3.72%
ALEC - DNLI
57%
Loosely correlated
+3.44%
JANX - DNLI
55%
Loosely correlated
-5.02%
RCKT - DNLI
54%
Loosely correlated
-1.92%
LGND - DNLI
54%
Loosely correlated
+4.47%
More